Key facts
- This page summarizes Michael Egholm's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 09 Apr 2024, 19:11.
Michael Egholm - 08 Apr 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- LAB
- Reported as of
- 08 Apr 2024
- Net transaction value
- -$277,948
- SEC form
- 4
- Accepted by SEC
- 09 Apr 2024, 19:11:29 UTC
- Prior SEC filing
- 05 Apr 2024
- Next SEC filing
- 21 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Egholm by Agnieszka Gallagher, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Egholm filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 09 Apr 2024.
Change
- Previous filing in this sequence was filed on 05 Apr 2024.
- Current net transaction value: -$277,948.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LAB
transaction
Common Stock
Tax liability
- Transaction value
- $277,948
- Shares
- -102,564
- Change %
- -16%
- Price
- $2.71
- Shares after
- 531,592
- Date
- 08 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain performance-based restricted stock units ("RSUs") granted to the reporting person on April 11, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 5, 2024 upon the determination by the Board of Directors of the Issuer that certain of the performance-based conditions were met.